Epinephrine Dose: Optimal Versus Standard Evaluation Trial
EpiDOSE
CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)
1 other identifier
interventional
3,790
1 country
8
Brief Summary
The objective of this randomized controlled trial is to evaluate the effectiveness of a low cumulative dose of epinephrine compared to a standard cumulative dose of epinephrine during resuscitation from ventricular fibrillation (VF) or ventricular tachycardia (VT) in adult out-of-hospital cardiac arrest (OHCA) patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started May 2023
Longer than P75 for phase_4
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 7, 2018
CompletedFirst Posted
Study publicly available on registry
February 1, 2019
CompletedStudy Start
First participant enrolled
May 24, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
December 11, 2025
December 1, 2025
4.5 years
November 7, 2018
December 9, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival to hospital discharge
Individuals discharged alive from hospital
Through study completion (up to 5 years)
Secondary Outcomes (14)
Return of spontaneous circulation in out-of-hospital setting
Through study completion (up to 5 years)
Survival to emergency department arrival
Through study completion (up to 5 years)
Survival to admission with death prior to discharge
Through study completion (up to 5 years)
Survival to discharge outside of a long-term healthcare facility e.g. nursing home
Through study completion (up to 5 years)
Modified Rankin Scale (mRS) score
12+/-3 months
- +9 more secondary outcomes
Study Arms (2)
Low Dose Epinephrine
ACTIVE COMPARATOREpinephrine up to 2mg total
Standard Dose Epinephrine
ACTIVE COMPARATOREpinephrine up to 6mg total
Interventions
Epinephrine 1mg 1:10000 (10cc) per dose
Eligibility Criteria
You may qualify if:
- Out-of-hospital cardiac arrest treated by paramedics
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire)
- Established intravenous vascular access
You may not qualify if:
- Known or apparent age \<18 years
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or confirmed by paramedics
- Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
- Administration of intramuscular, endotracheal tube, or intraosseous epinephrine
- Prisoners or persons in police custody
- Known allergy or sensitivity to epinephrine
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Unity Health Torontolead
- Canadian Institutes of Health Research (CIHR)collaborator
- Pfizercollaborator
Study Sites (8)
British Columbia Emergency Health Services (BCEHS)
Victoria, British Columbia, V8W 9P1, Canada
Peel Regional Paramedic Services
Brampton, Ontario, L6T 4B9, Canada
Middlesex-London Paramedic Service
London, Ontario, N6E 1R4, Canada
Halton Region Paramedic Services
Oakville, Ontario, L6M 3L1, Canada
Ottawa Paramedic Services
Ottawa, Ontario, K1H 1E2, Canada
Superior North Emergency Medical Services
Thunder Bay, Ontario, P7B 4X6, Canada
Essex-Windsor Emergency Health Services
Windsor, Ontario, N9A 1N6, Canada
Medavie Health Services West
Saskatoon, Saskatchewan, S7J 4M2, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paul Dorian, MD, MSc
Unity Health Toronto
- PRINCIPAL INVESTIGATOR
Steve Lin, MD, MSc
Unity Health Toronto
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2018
First Posted
February 1, 2019
Study Start
May 24, 2023
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2028
Last Updated
December 11, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share